NCT03713242View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 26, 2018

Primary Completion Date

February 27, 2020

Study Completion Date

February 27, 2020

Conditions
Hepatic Impairment
Interventions
DRUG

ACT-541468 25 mg

Administered as a tablet.

DRUG

ACT-541468 25 mg (or 10 mg depending on interim results)

Administered as a tablet.

Trial Locations (1)

4031

University Hospital Basel, Basel

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT03713242 - A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment | Biotech Hunter | Biotech Hunter